Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10503517" target="_blank" >RIV/00064165:_____/25:10503517 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10503517

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=08p33_QXod" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=08p33_QXod</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjh.70128" target="_blank" >10.1111/bjh.70128</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice

Popis výsledku v původním jazyce

Diffuse large B-cell lymphoma (DLBCL) is a relatively well treatable disease with long-term cure rates between 60% and 70% following standard front-line immunochemotherapy R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone). Despite recent treatment advances, 30%-40% of DLBCL patients have primary refractory disease or experience a relapse; both associated with inferior survival outcomes. Importantly, none of the currently used prognostic tools can clearly identify these patients. Circulating tumour DNA (ctDNA) is a promising, non-invasive biomarker that has demonstrated prognostic value across multiple cancer types, including DLBCL. Prior studies have shown that ctDNA levels at diagnosis correlate with key DLBCL characteristics, such as clinical stage, serum lactate dehydrogenase (LDH) levels and international prognostic index (IPI) score. Early ctDNA clearance during treatment has been associated with better response rates and superior survival outcomes in DLBCL patients. However, further real-world data as well as randomized clinical trials are needed to support full ctDNA clinical integration for personalized DLBCL therapy. Therefore, we have analysed 44 DLBCL patients (Table S1), all treated with R-CHOP as a first-line chemoimmunotherapy and determined the baseline ctDNA levels and its dynamics using the CAncer Personalized Profiling by deep Sequencing approach and a custom panel of 521 genes. Methodological details are described in Supporting Informatio S1.

Název v anglickém jazyce

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice

Popis výsledku anglicky

Diffuse large B-cell lymphoma (DLBCL) is a relatively well treatable disease with long-term cure rates between 60% and 70% following standard front-line immunochemotherapy R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone). Despite recent treatment advances, 30%-40% of DLBCL patients have primary refractory disease or experience a relapse; both associated with inferior survival outcomes. Importantly, none of the currently used prognostic tools can clearly identify these patients. Circulating tumour DNA (ctDNA) is a promising, non-invasive biomarker that has demonstrated prognostic value across multiple cancer types, including DLBCL. Prior studies have shown that ctDNA levels at diagnosis correlate with key DLBCL characteristics, such as clinical stage, serum lactate dehydrogenase (LDH) levels and international prognostic index (IPI) score. Early ctDNA clearance during treatment has been associated with better response rates and superior survival outcomes in DLBCL patients. However, further real-world data as well as randomized clinical trials are needed to support full ctDNA clinical integration for personalized DLBCL therapy. Therefore, we have analysed 44 DLBCL patients (Table S1), all treated with R-CHOP as a first-line chemoimmunotherapy and determined the baseline ctDNA levels and its dynamics using the CAncer Personalized Profiling by deep Sequencing approach and a custom panel of 521 genes. Methodological details are described in Supporting Informatio S1.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Haematology

ISSN

0007-1048

e-ISSN

1365-2141

Svazek periodika

207

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

2135-2139

Kód UT WoS článku

001567665800001

EID výsledku v databázi Scopus

2-s2.0-105015404716